Loading company
iBio, Inc.
IBIO · Nasdaq · ·
Next earnings: November 11, 2026
$1.18+0.9%Sep 29 close
- 1M
- -13.6%
- 6M
- -31.3%
- 1Y
- +41.9%
- 5Y
- -99.8%
IBIO · Nasdaq · ·
Next earnings: November 11, 2026
$1.18+0.9%Sep 29 close
iBio, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $200K | -100.00% |
| Profit | -$10.6M | -$5.2M | -105.33% |
| Profit per share | -$0.07 | -$0.31 | +77.42% |
| Free Cash Flow | -$6.2M | -$4.6M | -35.33% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from iBio, Inc.’s Item 2.02 8-K filed August 28, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
iBio, Inc. has no earnings call transcript available.